Ruxolitinib

Pre-clinicalCompleted

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Polycythemia Vera

Conditions

Polycythemia Vera

Trial Timeline

— → —

NCT ID

NCT05269771

About Ruxolitinib

Ruxolitinib is a pre-clinical stage product being developed by Novartis for Polycythemia Vera. The current trial status is completed. This product is registered under clinical trial identifier NCT05269771. Target conditions include Polycythemia Vera.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (16)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05269771	Pre-clinical	Completed	—	—	Polycythemia Vera
NCT04745637	Pre-clinical	Active	—	—	Primary Myelofibrosis (PMF)
NCT04337359	Pre-clinical	Completed	—	—	Severe/Very Severe COVID-19 Illness
NCT06824103	Approved	Recruiting	Sep 9, 2025	Jan 11, 2032	Graft vs. Host Disease
NCT06462469	Approved	Recruiting	Jul 4, 2024	Feb 17, 2028	Steroid-refractory Acute Graft Versus Host Disease
NCT03491215	Phase 1/2	Completed	Feb 21, 2019	Feb 2, 2023	Acute Graft Versus Host Disease
NCT02966353	Phase 2	Completed	Mar 31, 2017	Feb 15, 2019	Primary Myelofibrosis
NCT02292446	Phase 3	Completed	Nov 21, 2014	Dec 29, 2017	Polycythemia Vera
NCT02091752	Phase 2	Terminated	Sep 1, 2014	Feb 1, 2015	Primary Myelofibrosis
NCT02049450	Phase 2	Completed	May 28, 2014	Apr 12, 2016	Thalassemia Major
NCT02072057	Phase 2	Terminated	Apr 20, 2014	Nov 30, 2018	Cancer Cachexia
NCT02015208	Phase 1/2	Completed	Apr 1, 2014	Jul 1, 2015	Chronic Lymphocytic Leukemia
NCT02087059	Phase 3	Completed	Apr 1, 2014	Apr 1, 2015	Primary Myelofibrosis (MF)
NCT01877005	Phase 2	Completed	Jul 4, 2013	Jun 12, 2018	Hodgkin's Lymphoma
NCT01317875	Phase 1	Completed	Mar 31, 2011	Dec 31, 2019	Myelofibrosis
NCT01392443	Phase 2	Completed	Oct 14, 2010	Oct 31, 2017	Primary Myelofibrosis (MF)

Competing Products

20 competing products in Polycythemia Vera

See all competitors

Product	Company	Stage	Hype Score
Sapablursen + Placebo	Ono Pharmaceutical	Phase 3	77
Ruxolitinib + Abemaciclib	Eli Lilly	Phase 1	33
Bomedemstat	Merck	Phase 2	52
Ruxolitinib + Hydroxycarbamide + Interferon-Alpha	Novartis	Phase 3	77
ruxolitinib tablets	Novartis	Phase 3	77
Ruxolitinib	Novartis	Phase 3	77
Ruxolitinib + BAT	Novartis	Phase 2	52
Hydroxyurea	Novartis	Approved	85
Best Available Therapy + Ruxolitinib	Novartis	Phase 3	77
Smac Mimetic LCL161	Novartis	Phase 2	52
PEGASYS + Aspirin	Roche	Phase 2	52
RG7388 + Pegasys	Roche	Phase 1	33
Idasanutlin	Roche	Phase 2	52
PEGASYS + Hydroxyurea + Aspirin	Roche	Phase 3	77
Ropeginterferon alfa-2b	PharmaEssentia	Phase 2	51
Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen	PharmaEssentia	Phase 3	76
Pegylated-Proline-interferon alpha-2b + Best available therapy (BAT)	PharmaEssentia	Phase 3	76
Ropeginterferon alfa-2b	PharmaEssentia	Approved	84
P1101 + Low-dose aspirin	PharmaEssentia	Phase 2	51
P1101 (Ropeginterferon alfa-2b)	PharmaEssentia	Phase 3	76

Other Products from Novartis

LCZ696Approved

zoledronic acidApproved

NateglinideApproved

TenofovirApproved

FTY720Approved